Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-genes: siRNA, ribozymes and antisense.

Kevin J Scanlon1

  • 1Keck Graduate Institute, 535 Watson Dr., Claremont, CA. 91711, USA. kevin_scanlon@kgi.edu

Current Pharmaceutical Biotechnology
|November 17, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Commercializing medical technology.

Cytotechnology·2008
Same author

Construction and transfection of a ribozyme targeting human caspase-3.

Anticancer research·2004
Same author

Cancer gene therapy: challenges and opportunities.

Anticancer research·2004
Same author

Ribozyme against mutant K-ras mRNA suppresses tumor growth of pancreatic cancer.

International journal of oncology·2004
Same author

Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene.

International journal of oncology·2002

Scientists are advancing anti-gene technologies like oligodeoxynucleotides (ODNs), ribozymes, and short interfering RNA (siRNA) for gene therapy. Overcoming delivery challenges will enable precise gene targeting for treating human diseases.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Genomics

Background:

  • For thirty years, research has focused on selectively inhibiting genes in diseased tissues.
  • Early strategies included oligodeoxynucleotides (ODNs) and ribozymes, facing limitations in delivery and clinical utility.
  • Short interfering RNA (siRNA) is a rapidly advancing anti-gene technology with therapeutic potential.

Purpose of the Study:

  • To review the progress and challenges in anti-gene technology.
  • To explore the convergence of genomic knowledge and digital communication for disease treatment.
  • To highlight the potential of anti-gene molecules in understanding the human genome and developing gene therapies.

Main Methods:

  • Review of historical and current anti-gene strategies (ODNs, ribozymes, siRNA).

Related Experiment Videos

  • Analysis of advancements in genomic knowledge and digital communication.
  • Assessment of challenges and opportunities for anti-gene therapeutic applications.

    • Main Results:

    • Significant progress has been made in developing anti-gene molecules for gene silencing.
    • Ribozymes demonstrated gene knockdown in tumors but faced delivery hurdles.
    • siRNA technology shows promise for faster clinical impact if limitations are addressed.

    Conclusions:

    • The anti-gene field is poised to benefit from advances in genomics and digital technology.
    • Overcoming delivery challenges is crucial for the clinical success of anti-gene therapies.
    • Anti-gene molecules offer a promising avenue for understanding the human genome and developing future gene therapies.